- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Podcast
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
Author(s):
This episode highlights findings from an investigative study exploring the molecular targeting of biologics for psoriasis, the IL-17 drug class, how bimekizumab is different, plus more.
This episode highlights findings from an investigative study exploring the molecular targeting of biologics for psoriasis, as well as discusses the interleukin(IL)-17 class of biologics, how this class compares to other classes such as IL-23 and TNFα, and how bimekizumab (UCB) sets itself apart from other biologics in the pipeline for psoriasis.
Related Videos
Mechanism of Action Differences Among IL-17 Inhibitors
The Role of IL-17 in Psoriasis Pathogenesis
Pipeline Updates on the Horizon From Arcutis Biotherapeutics
LaShell Robinson on Takeda’s Initiative to Improve Research Diversity
Topical Corticosteroids: Potency, Vehicles, and Best Practices
Bunick Highlights Efficacy and Safety of JAK Inhibitors
Efficient Screening for Psoriatic Arthritis
Jeff Stark, MD: Enhancing Flexibility and Personalized Treatment with 320 mg Bimekizumab Dosage
Updating Treatment Guidelines: Incorporating Novel Therapies to Address Unmet Needs
When to Discontinue Treatment: Interpreting Safety Signals and Adverse Event Patterns
Related Content
